01:16:46,480 --> 01:17:03,480 also for other extra nodal diffuse large B cell lymphomas of IABC type rising from different size, such as breast or adrenal. 292 01:17:03,480 --> 01:17:28,480 And this was the topic of a long discussion among the clinical advisory committee that at the end concluded that at the time being, there is not enough information to conclude that these lymphomas are homogeneous clinical entity. 293 01:17:28,480 --> 01:17:50,480 And one should recognize this group of lymphoma as they serve in more specific studies, but at this moment not as distinct entities, such as lymphomas of the testis and the CNS. 294 01:17:50,480 --> 01:18:08,480 This table shows the classification of high grade B cell lymphoma and the HCV8 associated lymphomas. And there have been two important changes in this regard. 295 01:18:08,480 --> 01:18:30,480 Their recognition as entity of lymphomas names double little lymphoma with me B-CL2 rearrangement in both classification, ICC and WHO 5th edition.
48 00:10:15,480 --> 00:10:21,480 Yes, Mr. Sumit, please, you can start in, I'll give you the count, 3, 2, 1, please go ahead. 49 00:10:21,480 --> 00:10:28,480 Good morning, eminent faculty members and participants who have joined us from various parts of India and abroad. 50 00:10:28,480 --> 00:10:35,480 I am Sumit Kumar Madan from Zydus Life Sciences Limited and on behalf of Mumbai Hematology Group and Green Zydus, 51 00:10:35,480 --> 00:10:42,480 I welcome our keynote speaker for this Sunday's special academic feast, Professor Runangelo Fallingu,
01:17:29 to see if lymphoma is present or not i think i mean the only other thing that i would mention again it really relates to the gastric malt lymphomas where you can find that the clone is still there but you can't see anything and those patients still tend to do well you know they can have disease that's that's basically gone as long as the helicobacter doesn't come back so i'm afraid that's that's the only advice that i i could give you thank you sure thank you doctor sorry my beat uh there it is so uh thank
25:30 Sunday Quiz 29:00 Weekly case : Secondary triple positive APS 33:00 Thrombocytosis in SLE 34:30 Autosplenectomy 38:00 Challenges in setting up a BMT unit in LMIC 41:12 APBMT 22 countries 42:10 Minimal standards 51:30 National Guidelines for HCT (ICMR) 55:35 Book chapter by Dr Joseph John and Dr Mammen Chandy 56:25 Physical Design 1:01:40 HVAC 1:06:40 Cure2Children Approach 1:07:48 Basic Equipment 1:08:10 List of essential drugs for pediatric BMT and lab tests
17:00 Age vs survival 20:05 ALCL 23:05 Nodal TFH 24:20 PTCL 25:05 ENTNKcL 30:05 Histopathology 33:30 Alk negative ALCL - Donut cells, less EMA, no cytotoxic pattern 35:50 PTCL, NOS histopath 37:55 Alk neg ALCL vs PTCL 38:35 AITL 40:15 TFH lymphomas 45:25 Prognostic scoring 47:38 Treatment: CHOP vs Gem vs Bevacizumab vs Alemtuzumab 49:33 Addition of Etoposide - less than 60 yrs, normal LDH, Alk positive, (nodal PTCL) 50: 40 DA EPOCH 50:55 Echelon 2 52:35 Addition of oral azacitidine to CHOP 54:00 RoCHOP 54: 30 Role of Transplant 57:30 Role of Radiation 58:20 Newer agents 59:16 NKTCL - Chinese SWOG/ALSG staging 1:00:12 Prognostic scoring system - IPI, KPI, PINK, NRI 1:00:37 Treatment of NKTCL
Sir I am from Lahore. Excellent and extremely useful presentation. Please have more such useful presentations, so that I can benefit more from u. dr Fareed.
I was recently diagnosed with t cell lgl. I have some of the cd markers but currently on the watch and wait protocols. Why are these specific types more fatal?
